Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2003 Mar;79(929):127-32.
doi: 10.1136/pmj.79.929.127.

Thalidomide and its derivatives: emerging from the wilderness

J N Gordon  1 , P M Goggin
Affiliations
Review

Thalidomide and its derivatives: emerging from the wilderness

J N Gordon et al. Postgrad Med J. 2003 Mar.

Abstract

Forty years on from its worldwide withdrawal, thalidomide is currently undergoing a remarkable renaissance as a novel and powerful immunomodulatory agent. Over the last decade it has been found to be active in a wide variety of inflammatory and malignant disorders where conventional therapies have failed. Recently, considerable progress has been made in elucidating its complex mechanisms of action, which include both anticytokine and antiangiogenic properties. However, in addition to its well known teratogenic potential, it has a significant side effect profile that leads to cessation of treatment in up to 30% of subjects. In response to this, two new classes of potentially safer and non-teratogenic derivatives have recently been developed. This review summarises the biological effects, therapeutic applications, safety profile, and future potential of thalidomide and its derivatives.

PubMed Disclaimer

References

    1. J Exp Med. 1993 Jun 1;177(6):1675-80 - PubMed
    1. Arch Dermatol. 1994 Jan;130(1):66-9 - PubMed
    1. Proc Natl Acad Sci U S A. 1994 Apr 26;91(9):4082-5 - PubMed
    1. Chem Pharm Bull (Tokyo). 1994 May;42(5):1157-9 - PubMed
    1. Clin Exp Immunol. 1995 Feb;99(2):160-7 - PubMed

MeSH terms